Organon vs Perrigo
Organon reported revenue of $6.2 billion in fiscal 2025, 1.5 times Perrigo's $4.3 billion in fiscal 2025. Organon's revenue fell 2.9% in its latest year, and Perrigo's fell 2.8%. Free cash flow was $538 million at Organon and $145 million at Perrigo.
Side by side
| Organon | Perrigo | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $6.2B | $4.3B |
| Revenue growth | −2.9% | −2.8% |
| Revenue growth a year, last 5 years | −1.0% | 0.8% |
| Gross margin | 53.3% | 35.1% |
| Operating margin | — | −26.4% |
| Net margin | 3.0% | −33.5% |
| Free cash flow | $538M | $145M |
| Free cash flow margin | 8.7% | 3.4% |
| Return on capital | 5.3% | −13.2% |
| Net debt to EBITDA | 6.3x | — |
| Dividends and buybacks | $88M | $159M |
| Change in diluted share count | 0.6% | 0.8% |
| Last close | $13.74 | $15.82 |
| P/E at the last close | 17.6× | — |
| Insider trades, last 12 months | bought $854,704, sold $200,307 | bought $106,350, sold $0 |
| Piotroski F-score | 5 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
OrganonPerrigo
Operating margin
Percent of revenue
OrganonPerrigo
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
OrganonPerrigo